Recurrent fusions involving MLL and members of the super-elongation complex, such as AF4 and AF9, account for 10–30% of secondary and infant acute myeloid leukemia (AML) (Mitelman et al., 2007; Mertens et al., 2015). Here, KMT2A is linked to acute myeloid leukemia.